NEW: WINLEVI® (clascoterone)

LOCALLY REDUCE SEBUM PRODUCTION
IN ACNE VULGARIS1

Adverse events should be reported.

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd
medical_information@glenmarkpharma.com or call 0800 458 0383.

1. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.

FIRST-IN-CLASS, INNOVATIVE TOPICAL ANDROGEN-RECEPTOR INHIBITOR1

  • WINLEVI® (clascoterone) 10 mg/g cream is indicated for the treatment of facial acne vulgaris in adolescents from 12 years of age and older and treatment of acne vulgaris in adults, both males and females.2

  • WINLEVI® is the ONLY topical anti-androgen specifically developed to locally reduce sebum.1

  • WINLEVI® is the FIRST androgen-receptor inhibitor appropriate for the use in both FEMALE and MALE acne patients for the treatment of facial acne vulgaris in adolescents from 12 years of age and older and treatment of acne vulgaris in adults.1,2

1. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.
2. WINLEVI® Summary of Product Characteristics.

Explore more

By clicking this link, you are leaving the WINLEVI® website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to continue, please click Continue, otherwise click Stay on page.